Study Data from Infectious Diseases Department Update Understanding of Chronic Hepatitis B Virus (Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D).
In: Hepatitis Weekly, 2024-04-15, S. 2791-2791
serialPeriodical
Zugriff:
A recent study conducted by the Infectious Diseases Department provides new insights into the treatment of chronic hepatitis B virus (HBV). The study focused on the use of pegylated interferon alpha 2a as a treatment for chronic hepatitis D, a co-infection with HBV. The research found that after 24 weeks of treatment, patients who achieved undetectable HDV RNA had long-term suppression of the virus. However, the study also noted that relapses were common, with more than 50% of patients experiencing a relapse. The research suggests that the virologic response at week 24 can help determine which patients will benefit from continuing treatment. [Extracted from the article]
Copyright of Hepatitis Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Study Data from Infectious Diseases Department Update Understanding of Chronic Hepatitis B Virus (Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D).
|
---|---|
Zeitschrift: | Hepatitis Weekly, 2024-04-15, S. 2791-2791 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1086-0223 (print) |
Schlagwort: |
|
Sonstiges: |
|